Israel’s Biolojic Design (see here previously) is partnering Merck, to develop molecules that could be the basis for therapies to treat cancer and other immunological disorders. The venture is potentially worth up to 350 million euros to the Israeli company.

https://www.calcalistech.com/ctechnews/article/bybenkovr